| Display title | Chemistry:Lesopitron |
| Default sort key | Lesopitron |
| Page length (in bytes) | 2,635 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 804592 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>MainAI |
| Date of page creation | 02:31, 6 February 2024 |
| Latest editor | imported>MainAI |
| Date of latest edit | 02:31, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones. In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD). It made it to phase II clinical trials but was apparently discontinued... |
